Publications
Below you can find a list of our published research.
Below you can find a list of our published research.
511 results
Cited 31 times since 2010 (2.2 per year) source: EuropePMC
Annals of oncology : official journal of the European Society for Medical Oncology, Volume 22, Issue 1, 1 1 2010, Pages 132-138 Outcomes of concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer and significant comorbidity. Phernambucq ECJ, Spoelstra FOB, Verbakel WFAR, Postmus PE, Melissant CF, Maassen van den Brink KI, Frings V, van de Ven PM, Smit EF, Senan S
Background: published trials of concurrent chemoradiotherapy (CCRT) in stage III non-small-cell lung cancer (NSCLC) generally excluded patients with significant comorbidity. We evaluated outcomes in patients who were selected by using radiation planning parameters and were considered, despite comorbidity, fit enough to receive cisplatin-based chemotherapy. Patients and methods: from 2003 to 2008, 89 patients with stage III NSCLC fit to receive cisplatin-based chemotherapy and a V(20) Abstract
Cited 6 times since 2010 (0.4 per year) source: EuropePMC
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, Volume 29, Issue 10, 26 4 2010, Pages 1150-1158 Long-term outcomes in pulmonary arterial hypertension in the first-line epoprostenol or first-line bosentan era. Jacobs W, Boonstra A, Brand M, Rosenberg DM, Schaaf B, Postmus PE, Vonk Noordegraaf A
Background: The aim of this study was to describe the long-term outcomes in idiopathic pulmonary arterial hypertension (IPAH) treated with first-line bosentan or intravenous (IV) epoprostenol, and additional therapy as needed. Methods: In a single-center, retrospective, longitudinal cohort, data on right heart catheterization, 6-minute walk distance (6MWD), disease progression and mortality were collected. Outcomes were assessed in first-line bosentan and first-line epoprostenol patients. To red... Abstract
Cited 56 times since 2010 (4 per year) source: EuropePMC
Chest, Volume 138, Issue 6, 21 3 2010, Pages 1395-1401 Progressive dilatation of the main pulmonary artery is a characteristic of pulmonary arterial hypertension and is not related to changes in pressure. Boerrigter B, Mauritz GJ, Marcus JT, Helderman F, Postmus PE, Westerhof N, Vonk-Noordegraaf A
Background: Pulmonary artery (PA) dilatation is one of the consequences of pulmonary arterial hypertension (PAH) and is used for noninvasive detection. However, it is unclear how the size of the PA behaves over time and whether it is related to pressure changes. The aim of this study was to evaluate PA size during follow-up in treated patients with PAH and whether it reflects pulmonary vascular hemodynamics. Methods: Fifty-one patients with PAH who underwent at least two right-sided heart cathet... Abstract
Cited 27 times since 2010 (1.9 per year) source: EuropePMC
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, Volume 5, Issue 5, 1 1 2010, Pages 719-720 Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report. Smit EF, Dingemans AM, Thunnissen FB, Hochstenbach MM, van Suylen RJ, Postmus PE
Cited 25 times since 2010 (1.8 per year) source: EuropePMC
European journal of heart failure, Volume 12, Issue 7, 22 4 2010, Pages 716-720 Exercise stroke volume and heart rate response differ in right and left heart failure. Groepenhoff H, Westerhof N, Jacobs W, Boonstra A, Postmus PE, Vonk-Noordegraaf A
Aims: In pulmonary arterial hypertension (PAH), the exercise-induced increase in stroke volume (SV) is limited by the increase in pulmonary artery pressure. In left heart failure (LHF), systemic arterial pressure increases little during exercise, and the SV increase is limited by the left ventricle itself. These differences might be reflected by a dissimilar SV and heart rate (HR) response to exercise, which could have important therapeutic implications, for example in beta-blocker therapy. Ther... Abstract
Cited 50 times since 2010 (3.6 per year) source: EuropePMC
Clinical cancer research : an official journal of the American Association for Cancer Research, Volume 16, Issue 11, 15 3 2010, Pages 3078-3087 A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer. Lind JS, Dingemans AM, Groen HJ, Thunnissen FB, Bekers O, Heideman DA, Honeywell RJ, Giovannetti E, Peters GJ, Postmus PE, van Suylen RJ, Smit EF
Purpose: This multicenter, phase II study evaluates the efficacy and safety of erlotinib, an epidermal growth factor receptor (EGFR) inhibitor, plus sorafenib, a multityrosine kinase inhibitor against vascular endothelial growth factor receptors, in patients with previously untreated advanced non-small cell lung cancer (NSCLC). Experimental design: Chemotherapy-naïve patients with stage IIIB/IV NSCLC received erlotinib (150 mg once a day) and sorafenib (400 mg twice a day) until disease progress... Abstract
Cited 16 times since 2010 (1.1 per year) source: EuropePMC
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, Volume 5, Issue 4, 1 1 2010, Pages 554-557 Osteoblastic bone lesions developing during treatment with erlotinib indicate major response in patients with non-small cell lung cancer: a brief report. Lind JS, Postmus PE, Smit EF
Background: The osteoblastic bone flare or response is the paradoxical phenomenon of increase in the quantity and/or density of bone lesions in the presence of well-documented disease response to treatment in other tumor sites. It results from the rapid repair and increased osteoblastic activity in bone metastases responding to therapy and therefore represents treatment efficacy. Nevertheless, no reliable markers can differentiate an osteoblastic flare or response from disease progression. In no... Abstract
Cited 50 times since 2010 (3.5 per year) source: EuropePMC
The European respiratory journal, Volume 36, Issue 4, 29 5 2010, Pages 800-807 Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil. Mouchaers KT, Schalij I, de Boer MA, Postmus PE, van Hinsbergh VW, van Nieuw Amerongen GP, Vonk Noordegraaf A, van der Laarse WJ
Pulmonary arterial hypertension (PAH) still cannot be cured, warranting the search for novel treatments. Fasudil (a Rho kinase inhibitor) was compared with bosentan (an endothelin receptor blocker) and sildenafil (a phosphodiesterase 5 inhibitor), with emphasis on right ventricular (RV) function, in a reversal rat model of monocrotaline (MCT)-induced PAH. In addition, the effects of combining bosentan or sildenafil with fasudil were studied. MCT (40 mg·kg body weight(-1)) induced clear PAH in ma... Abstract
Cited 12 times since 2010 (0.8 per year) source: EuropePMC
The European respiratory journal, Volume 36, Issue 2, 14 2 2010, Pages 261-268 Genetic and environmental influences on objective intermediate asthma phenotypes in Dutch twins. Wu T, Boezen HM, Postma DS, Los H, Postmus PE, Snieder H, Boomsma DI
It is unclear to what extent the same set of environmental or genetic factors regulate objective intermediate asthma phenotypes. We examined heritabilities of these phenotypes and estimated their environmental and genetic overlap. We studied baseline lung function (forced expiratory volume in 1 s (FEV(1)), forced vital capacity (FVC) and FEV(1)/FVC), bronchial hyperresponsiveness, number of positive skin prick tests (SPT) to 11 allergens, serum total immunoglobulin (Ig)E, number of positive spec... Abstract
Cited 11 times since 2009 (0.8 per year) source: EuropePMC
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, Volume 4, Issue 12, 1 1 2009, Pages 1585-1586 Dramatic response to low-dose erlotinib of epidermal growth factor receptor mutation-positive recurrent non-small cell lung cancer after severe cutaneous toxicity. Lind JS, Postmus PE, Heideman DA, Thunnissen EB, Bekers O, Smit EF
Erlotinib is increasingly being used for the treatment of non-small cell lung cancer. The recommended dose is 150 mg/day and no efficacy data is available for lower doses. We describe a case of dramatic tumor response to 50 mg erlotinib in a patient with EGFR mutation positive NSCLC who developed a severe rash on full dose erlotinib. Rash is known to correlate with response and survival in patients treated with erlotinib. Our case suggests that in the presence of rash, dose reductions to "s... Abstract
Cited 7 times since 2009 (0.5 per year) source: EuropePMC
Allergy, Volume 64, Issue 11, 1 1 2009, Pages 1623-1628 Association and interaction analyses of eight genes under asthma linkage peaks. Ferreira MA, Zhao ZZ, Thomsen SF, James M, Evans DM, Postmus PE, Kyvik KO, Backer V, Boomsma DI, Martin NG, Montgomery GW, Duffy DL
Background: Linkage studies have implicated the 2q33, 9p21, 11q13 and 20q13 regions in the regulation of allergic disease. The aim of this study was to test genetic variants in candidate genes from these regions for association with specific asthma traits. Methods: Ninety-five single nucleotide polymorphisms (SNP) located in eight genes (CD28, CTLA4, ICOS, ADAM23, ADAMTSL1, MS4A2, CDH26 and HRH3) were genotyped in >5000 individuals from Australian (n = 1162), Dutch (n = 99) and Danish (n = 30... Abstract
Cited 58 times since 2009 (4 per year) source: EuropePMC
American journal of physiology. Heart and circulatory physiology, Volume 297, Issue 6, 2 1 2009, Pages H2154-60 RC time constant of single lung equals that of both lungs together: a study in chronic thromboembolic pulmonary hypertension. Saouti N, Westerhof N, Helderman F, Marcus JT, Stergiopulos N, Westerhof BE, Boonstra A, Postmus PE, Vonk-Noordegraaf A
The product of resistance, R, and compliance, C (RC time), of the entire pulmonary circulation is constant. It is unknown if this constancy holds for individual lungs. We determined R and C in individual lungs in chronic thromboembolic pulmonary hypertension (CTEPH) patients where resistances differ between both lungs. Also, the contribution of the proximal pulmonary arteries (PA) to total lung compliance was assessed. Patients (n=23) were referred for the evaluation of CTEPH. Pressure was measu... Abstract
Cited 233 times since 2009 (15.9 per year) source: EuropePMC
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, Volume 4, Issue 9, 1 1 2009, Pages 1049-1059 The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. Vallières E, Shepherd FA, Crowley J, Van Houtte P, Postmus PE, Carney D, Chansky K, Shaikh Z, Goldstraw P, International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions
Introduction: For more than 50 years, small cell lung cancer (SCLC) has been staged mainly as either limited or extensive stage disease. Small published series of resected SCLC have suggested that the tumor, node, metastases (TNM) pathologic staging correlates with the survival of resected patients. Recent analysis of the 8088 cases of SCLC in the International Association for the Study of Lung Cancer (IASLC) database demonstrated the usefulness of clinical TNM staging in this malignancy. The IA... Abstract
Cited 105 times since 2009 (7.2 per year) source: EuropePMC
The European respiratory journal, Volume 34, Issue 3, 1 1 2009, Pages 669-675 Effects of exercise training in patients with idiopathic pulmonary arterial hypertension. de Man FS, Handoko ML, Groepenhoff H, van 't Hul AJ, Abbink J, Koppers RJ, Grotjohan HP, Twisk JW, Bogaard HJ, Boonstra A, Postmus PE, Westerhof N, van der Laarse WJ, Vonk-Noordegraaf A
We determined the physiological effects of exercise training on exercise capacity and quadriceps muscle function in patients with idiopathic pulmonary arterial hypertension (iPAH). In total, 19 clinically stable iPAH patients (New York Heart Association II-III) underwent a supervised exercise training programme for the duration of 12 weeks. Maximal capacity, endurance capacity and quadriceps function were assessed at baseline and after 12 weeks. In 12 patients, serial quadriceps muscle biopsies... Abstract
Cited 6 times since 2009 (0.4 per year) source: EuropePMC
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, Volume 36, Issue 6, 17 3 2009, Pages 1052-1057 Evaluation of a treatment strategy for optimising preoperative chemoradiotherapy in stage III non-small-cell lung cancer. Phernambucq EC, Spoelstra FO, Paul MA, Senan S, Melissant CF, Postmus PE, Smit EF
Objective: Concurrent chemoradiotherapy is standard of care in stage III non-small-cell lung cancer, although surgery may be beneficial in selected patients in whom induction therapy has achieved 'down-staging' of mediastinal nodal disease. Previous studies incorporated treatment 'splits' for re-evaluation, and such gaps lead to poorer survival in patients undergoing chemoradiotherapy. We describe the outcome of a treatment strategy to limit the duration of treatment splits.... Abstract
Cited 28 times since 2009 (1.9 per year) source: EuropePMC
Clinical cancer research : an official journal of the American Association for Cancer Research, Volume 15, Issue 14, 7 1 2009, Pages 4700-4705 Color fluorescence ratio for detection of bronchial dysplasia and carcinoma in situ. Lee P, van den Berg RM, Lam S, Gazdar AF, Grunberg K, McWilliams A, Leriche J, Postmus PE, Sutedja TG
Background: Autofluorescence bronchoscopy is more sensitive than conventional bronchoscopy for detecting early airway mucosal lesions. Decreased specificity can lead to excessive biopsy and increased procedural time. Onco-LIFE, a device that combines fluorescence and reflectance imaging, allows numeric representation by expressing red-to-green ratio (R/G ratio) within the region of interest. The aim of the study was to determine if color fluorescence ratio (R/G ratio) added to autofluorescence b... Abstract
Cited 124 times since 2009 (8.3 per year) source: EuropePMC
Circulation, Volume 120, Issue 1, 22 4 2009, Pages 42-49 Opposite effects of training in rats with stable and progressive pulmonary hypertension. Handoko ML, de Man FS, Happé CM, Schalij I, Musters RJ, Westerhof N, Postmus PE, Paulus WJ, van der Laarse WJ, Vonk-Noordegraaf A
Background: Exercise training in pulmonary arterial hypertension (PH) is a promising adjunct to medical treatment. However, it is still unclear whether training is beneficial for all PH patients. We hypothesized that right ventricular adaptation plays a pivotal role in the response to training. Methods and results: Two different dosages of monocrotaline were used in rats to model stable PH with preserved cardiac output and progressive PH developing right heart failure. Two weeks after injection,... Abstract
Cited 53 times since 2009 (3.6 per year) source: EuropePMC
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, Volume 4, Issue 6, 1 1 2009, Pages 679-683 The IASLC Lung Cancer Staging Project: data elements for the prospective project. Giroux DJ, Rami-Porta R, Chansky K, Crowley JJ, Groome PA, Postmus PE, Rusch V, Sculier JP, Shepherd FA, Sobin L, Goldstraw P, International Association for the Study of Lung Cancer International Staging Committee
The International Association for the Study of Lung Cancer Retrospective Staging Project culminated in a series of recommendations to the International Union Against Cancer and to the American Joint Committee on Cancer regarding the seventh edition of the tumor, node, metastasis (TNM) classification for lung cancer. The International Staging Committee of the International Association for the Study of Lung Cancer now issues this call for participation in the Prospective Project designed to assess... Abstract
Cited 25 times since 2009 (1.7 per year) source: EuropePMC
American journal of physiology. Heart and circulatory physiology, Volume 297, Issue 1, 24 4 2009, Pages H200-7 Endothelin receptor blockade combined with phosphodiesterase-5 inhibition increases right ventricular mitochondrial capacity in pulmonary arterial hypertension. Mouchaers KT, Schalij I, Versteilen AM, Hadi AM, van Nieuw Amerongen GP, van Hinsbergh VW, Postmus PE, van der Laarse WJ, Vonk-Noordegraaf A
Pulmonary arterial hypertension (PAH) is often treated with endothelin (ET) receptor blockade or phosphodiesterase-5 (PDE5) inhibition. Little is known about the specific effects on right ventricular (RV) function and metabolism. We determined the effects of single and combination treatment with Bosentan [an ET type A (ET(A))/type B (ET(B)) receptor blocker] and Sildenafil (a PDE5 inhibitor) on RV function and oxidative metabolism in monocrotaline (MCT)-induced PAH. Fourteen days after MCT injec... Abstract
Cited 79 times since 2009 (5.2 per year) source: EuropePMC
The European respiratory journal, Volume 34, Issue 2, 12 2 2009, Pages 371-379 Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy. Overbeek MJ, Vonk MC, Boonstra A, Voskuyl AE, Vonk-Noordegraaf A, Smit EF, Dijkmans BA, Postmus PE, Mooi WJ, Heijdra Y, Grünberg K
Systemic sclerosis-associated pulmonary arterial hypertension (SScPAH) has a worse prognosis and response to pulmonary arterial hypertension (PAH) therapy than idiopathic PAH (IPAH). These differences have not yet been explained. Knowledge concerning histological pulmonary vasculopathy in SScPAH is limited in contrast to IPAH. Therefore, we explored patterns of vasculopathy in SScPAH compared with IPAH. Parameters of vasculopathy were assessed from lung tissue of eight PAH patients with limited... Abstract